Sociedad Argentina de Hematología












ISSN 2250-8309


Formulario de cesión
de Derechos de Autor

Se solicita enviar el siguiente formulario, debidamente firmado por todos los autores del trabajo presentado

por Fax (11) 48552452

o personalmente en la SAH
o en archivo PDF por mail

Formulario de Cesión de Derechos de Autor



  REVISTA ARGENTINA DE HEMATOLOGÍA                                                                                    « Back »

Volumen:    21    # Number : 1

Publication Date :    ENERO - ABRIL    Year:    2017


Use of brentuximab vedotin for refractory ALK negative anaplastic large cell lymphoma
Authors: Clavijo MM; Garate G; Aizpurua F; Mahuad C; Vicente A; Casali C; Cicco, JA; Zerga, M

Abstract: Introduction. Anaplastic large cell lymphoma ALK negative is an entity classified as part of peripheral T-cell neoplasm with CD30 uniform expression. Overall prognosis is usually poor, with a high rate of relapse after first line chemotherapy. Brentuximab vedotin is an antibody–drug conjugate that targets CD30, being an attractive treatment option. Case report: A 65 year old man, with past medical history of chronic obstructive pulmonary disease, presented with progressive nasal occlusion. A biopsy was taken from intranasal mass which revealed ALK negative anaplastic large cell lymphoma. He had multiple extranodal involvement. He received 6 cycles of chemotherapy with vincristine, prednisone, etoposide, cyclophosphamide and doxorubicin. Due to the presence of refractory disease, brentuximab vedotin was given. After three courses, severe pulmonary event appeared, so treatment was suspended but complete remission was obtained. He is now in plan of autologous stem cell transplantation. Discussion: ALK negative anaplastic large cell lymphoma is a disease with an unfortunate prognosis. Brentuximab vedotin has been reported to induce good objective and complete rate responses. Nevertheless, its long time remission is apparently poor, being the stem cell transplantation a considerable option of consolidation treatment in many centers.

Key words: anaplastic large cell lymphoma, CD30, brentuximab.

Pages :

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485